Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc., formerly Pain Therapeutics Inc.) is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam (formerly known as PTI-125 and sumifilam) as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| FLNA | FILANA THERAPEUTICS, INC. | 2026-10-29 12:14:33 | 0.66 | 0.02 | 3.31 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FLNA | 0001069530 | FILANA THERAPEUTICS, INC. | US14817C1071 | — | 911911336 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 6801 N CAPITAL OF TEXAS HIGHWAY | AUSTIN | TX | 78731 | UNITED STATES | US | 512-501-2444 | 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731 | 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX, 78731 | CASSAVA SCIENCES INC | Pharmaceuticals | 1998 | — | — | https://www.filanatx.com | 87,000,000 | 48,307,896 | 48,307,896 | Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc., formerly Pain Therapeutics Inc.) is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam (formerly known as PTI-125 and sumifilam) as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. | 2026-10-30 06:24:15 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 87,000,000 | -471,000,000 | -84.4086 | 48,307,896 | 0 | 0 |
| 2024 | 558,000,000 | -409,000,000 | -42.2958 | 48,307,896 | 5,082,685 | 11.7586 |
| 2023 | 967,000,000 | -133,000,000 | -12.0909 | 43,225,211 | 1,489,654 | 3.5693 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Eric J. Schoen | Chief Financial Officer | 2025 | 475,000 | 215,000 | 0 | — | 0 | 830,010 |
| Richard J. Barry | Chief Executive Officer, President | 2025 | 675,000 | 355,000 | 0 | — | 0 | 1,520,035 |
| Eric J. Schoen | Chief Financial Officer | 2024 | 475,000 | 250,000 | 0 | — | 0 | 3,850,772 |
| Remi Barbier | Chief Executive Officer, President | 2024 | 867,708 | 500,000 | 0 | — | 1,255,950 | 3,685,803 |
| Richard J. Barry | Chief Executive Officer, President | 2024 | 309,375 | 0 | 0 | — | 10,000 | 16,729,425 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 17 |
| 2024 | 30 |
| 2023 | 29 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 0 | 0 | 0 |
| Research And Development Expenses | 26,590,000 | 69,637,000 | 89,423,000 |
| General And Administrative Expenses | 68,800,000 | 71,809,000 | 16,534,000 |
| Operating Expenses | 95,390,000 | 141,446,000 | 105,957,000 |
| Operating Income | -95,390,000 | -141,446,000 | -105,957,000 |
| Net Income | -90,973,000 | -24,342,000 | -97,217,000 |
| Earnings Per Share Basic | -1.88 | -0.53 | -2.32 |
| Earnings Per Share Diluted | -1.88 | -1.46 | — |
| Weighted Average Shares Outstanding Basic | 48,297,000 | 46,329,000 | 41,932,000 |
| Weighted Average Shares Outstanding Diluted | 48,297,000 | 46,604,000 | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 95,502,000 | 128,574,000 | 121,136,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 64,000 | 38,000 | 287,000 |
| Total Assets Current | 97,709,000 | 136,532,000 | 129,633,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 20,646,000 | 20,964,000 | 21,854,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 20,646,000 | 21,001,000 | 22,030,000 |
| Total Assets | 118,355,000 | 157,533,000 | 151,663,000 |
| Accounts Payable | 41,647,000 | 7,654,000 | 10,573,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 198,000 | 299,000 | 385,000 |
| Total Liabilities Current | 43,834,000 | 11,750,000 | 14,195,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 118,000 | 79,000 | 0 |
| Total Liabilities Non Current | 118,000 | 79,000 | 0 |
| Total Liabilities | 43,952,000 | 11,829,000 | 14,195,000 |
| Common Stock | 48,000 | 48,000 | 42,000 |
| Retained Earnings | -496,084,000 | -405,111,000 | -380,769,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 74,403,000 | 145,704,000 | 137,468,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 903,000 | 952,000 | 1,084,000 |
| Share Based Compensation Expense | 19,582,000 | 16,291,000 | 4,586,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -6,080,000 | -539,000 | -1,714,000 |
| Change In Accounts Payable | 33,993,000 | -2,919,000 | 6,896,000 |
| Change In Other Liabilities | -62,000 | -7,000 | -304,000 |
| Cash From Operating Activities | -32,252,000 | -116,929,000 | -82,025,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 581,000 | 103,000 | 414,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -581,000 | -103,000 | -414,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 90,000 | 0 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -239,000 | 124,470,000 | 2,560,000 |
| Change In Cash | -33,072,000 | 7,438,000 | -79,879,000 |
| Cash At End Of Period | 95,502,000 | 128,574,000 | 121,136,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.88 | -0.53 | -2.32 |
| Price To Earnings Ratio | -1.0532 | -4.4528 | -9.7026 |
| Earnings Growth Rate | 254.717 | -77.1552 | — |
| Price Earnings To Growth Ratio | -0.0041 | 0.0577 | — |
| Book Value Per Share | 1.5405 | 3.145 | 3.2784 |
| Price To Book Ratio | 1.2853 | 0.7504 | 6.8662 |
| Ebitda | -90,070,000 | -23,390,000 | -96,133,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 585,000 | 62,000 | 74,000 |
| Free Cash Flow | -32,837,000 | -116,991,000 | -82,099,000 |
| Return On Equity | -1.2227 | -0.1671 | -0.7072 |
| One Year Beta | 0.944 | 1.4328 | 1.2385 |
| Three Year Beta | 1.113 | 1.1228 | 1.4694 |
| Five Year Beta | 1.3196 | 1.322 | 1.2554 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Barry Richard | Director, President & CEO | 2026-09-30 | 100,000 | A | 1,337,964 |
| Barry Richard | Director, President & CEO | 2026-09-29 | 206,813 | A | 1,237,964 |
| Barry Richard | Director, President & CEO | 2026-09-28 | 93,091 | A | 1,031,151 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Signature Equity Partners, LLC | 2026-09-30 | 1,772 | 2,000 | 0.886 |
| Caitong International Asset Management Co., Ltd | 2026-09-30 | 1 | 1 | 1 |
| MGO ONE SEVEN LLC | 2026-09-30 | 29,538 | 33,339 | 0.886 |
| Apollon Wealth Management, LLC | 2026-09-30 | 14,543 | 16,414 | 0.886 |
| Physician Wealth Advisors, Inc. | 2026-09-30 | 515 | 581 | 0.8864 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD WORLD FUND | 2026-08-31 | ETF Shares | VHT | 134,181 | 120,494.54 | 0.0005 |
| VANGUARD WORLD FUND | 2026-08-31 | Admiral Shares | VHCIX | 134,181 | 120,494.54 | 0.0005 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 72,474 | 65,081.65 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Total Market Index Fund | FSKAX | 81,461 | 73,151.98 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 9,088 | 8,161.02 | 0.0 |